<DOC>
	<DOCNO>NCT02687373</DOCNO>
	<brief_summary>This study conduct Siaya County Nyanza Province , western Kenya . Healthy child age 5 month 9 year age living within approximately 10 km study clinic ( ) ( Siaya County Referral Hospital , Wagai dispensary , government health facility Wagai division ) eligible participation Part 1 ; healthy infant age 5 month - 12 month inclusive eligible Part 2 .</brief_summary>
	<brief_title>Safety , Tolerability Efficacy PfSPZ Vaccine Healthy Children Infants 5 Months - 9 Years Living Kenya</brief_title>
	<detailed_description>Part 1 : Age De-Escalation Dose Escalation Part 1 trial randomize blinded evaluation safety tolerability PfSPZ Vaccine administer DVI healthy child infant live area high malaria transmission . A maximum 156 child 5 month 9 year inclusive vaccination enrol randomized receive vaccine normal saline ( NS ) placebo DVI . Total participation time dose escalation trial range 5-16 week per participant screen visit close 4 - 12 week enrolment close . Vaccination begin 5-9 year age group dosage 4.5 x10^5 PfSPZ . A single vaccination administer DVI 12 participant age 5-9 year ( inclusive ) age , 8 receive PfSPZ vaccine 4 participant receive NS placebo DVI , treatment allocation randomize double-blind . Once initial dose show well tolerate without safety concern , next high dose 9.0 x 10^5 PfSPZ administer second group 5-9 year old . Once show well tolerate without safety concern , high dose 1.8 x 10^6 PfSPZ give third group 5-9 year old concurrently low dose ( 1.35 x10^5 ) give same-sized group young child age 13-59 month . Two week later , dose escalate 2.7 x10^5 PfSPZ second group child age 13-59 month . Only dose show well-tolerated without safety concern PfSPZ Vaccine , low dose , give infant age 5 - 12 month . Within age group , dosages increase stepwise reach 1.8 x 10^6 PfSPZ , initiation group stagger least 2 week , provide safety threshold surpass . In dosage level , PfSPZ Vaccine placebo provide limited number participant day ( e.g . 3 participant one age group day 1 4 ) . The PfSPZ Vaccine dose increase next dose level safety assess subject first group . The procedure follow dos . Children age group enrol receive 2 high dos , i.e . 9.0 x 10^5 1.8 x 10^6 PfSPZ , placebo , receive second vaccination dose 8 week , provide first vaccination dose level show safety signal . Part 2 : Safety Efficacy Part study conduct outpatient area Siaya County Referral Hospital , large referral hospital western Kenya Wagai dispensary . A maximum 416 infant 5 M 12 M inclusive vaccination enrol safety efficacy trial randomize receive PfSPZ Vaccine dose determine Part 1 trial ( dose escalation ) , likely 4.5x10^5 , 9.0 x10^5and 1.8 x 10^6 administer x 3 dos ; NS placebo administer x 3 dos , DVI administer 8 week interval . Participants ( N = 416 , 104 study arm ) randomly assign double blind fashion receive one follow PfSPZ Vaccine regimes : Group 1 ( N=104 ) : The high dose determine safe well tolerated Part 1 trial , administer 3 dos DVI 0 , 8 16 week . Likely dosage 1.8 x 10^6 PfSPZ per dose . Group 2 ( N=104 ) : The second high dose , half high dose , administer 3 dos DVI 0 , 8 16 week . Likely dosage 9.0 x 10^5 PfSPZ per dose . Group 3 ( N=104 ) : A low dose ( half second high dose ) administer 3 dos DVI 0 , 8 , 16 week . Likely dosage 4.5x 10^5 PfSPZ per dose . Group 4 ( N=104 ) : A placebo arm , receive NS DVI , 3 time 8 week interval .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy child 5 month 9 year inclusive ( Part 1 ) healthy infant 512 month inclusive ( Part 2 ) HIV negative Able participate duration study . Parents/guardians age 18 year able willing provide inform consent/permission . The consent/permission writing . For adult parent guardian illiterate , impartial witness sign consent/permission form behalf parent parent/guardian provide thumb print . Positive HIV test breastfeeding infant child know HIV positive mother ( per Kenyan guideline , HIV expose breastfeed child cotrimoxazole ) Refusal HIV test Elevated ALT ( liver function test ) â‰¥2x ULN ( ALT &gt; 84 U/L ) Abnormal hematological parameter define : hemoglobin &lt; 8 g/dl , WBC &lt; 1500 / mm3 , neutrophils &lt; 750/ mm3 , platelet count &lt; 75.000/ mm3 Abnormal renal function test creatinine &gt; 0.9 mg/dL Known sickle cell disease Current use systemic immunosuppressant pharmacotherapy Current significant medical condition ( cardiac , hepatic , renal , hematological ) evidence serious underlie medical condition identify medical history , physical examination , laboratory examination History splenectomy History neurologic disorder ( include seizure , uncomplicated febrile seizure ) Known allergy component vaccine formulation , history anaphylactic response mosquitobites , know allergy first second line antimalarial use treat malaria Plan participate another investigational vaccine/drug research within 1 month study end Prior participation malaria vaccine trial Participation PfSPZ Vaccine Trial Part 1 ( Part 2 ) History illness condition , investigator 's judgment , may substantially increase risk associate subject 's participation protocol compromise scientific objective Child/orphan institutional care</criteria>
	<gender>All</gender>
	<minimum_age>5 Months</minimum_age>
	<maximum_age>9 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Plasmodium falciparum</keyword>
	<keyword>PfSPZ Vaccine</keyword>
</DOC>